Connect Biopharma Holdings Limited: cash and cash equivalents
Cash and cash equivalents for Connect Biopharma Holdings Limited. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Connect Biopharma Holdings Limited financial histories
What this measure means
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
Exact concept: us-gaap:CashAndCashEquivalentsAtCarryingValue. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2023-12-31 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-12-31 | 38,345,000 | USD | 2026-03-31 | 10-K · 0001835268-26-000013 |
| At date | 2024-12-31 | 78,232,000 | USD | 2026-03-31 | 10-K · 0001835268-26-000013 |
| At date | 2023-12-31 | 105,663,000 | USD | 2025-03-31 | 10-K · 0001835268-25-000014 |
Related financial histories
- Connect Biopharma Holdings Limited: total assets
- Connect Biopharma Holdings Limited: total liabilities
- Connect Biopharma Holdings Limited: stockholders equity
- Connect Biopharma Holdings Limited: net income or loss
- Connect Biopharma Holdings Limited: operating cash flow
- Connect Biopharma Holdings Limited: capital expenditure payments
- Connect Biopharma Holdings Limited: contract revenue excluding tax
- Connect Biopharma Holdings Limited: financing cash flow
- Connect Biopharma Holdings Limited: investing cash flow
- Connect Biopharma Holdings Limited: retained earnings or deficit
- Connect Biopharma Holdings Limited: basic weighted-average shares
- Connect Biopharma Holdings Limited: diluted weighted-average shares
- Connect Biopharma Holdings Limited: basic earnings per share
- Connect Biopharma Holdings Limited: diluted earnings per share
- Connect Biopharma Holdings Limited: income tax expense or benefit
- Connect Biopharma Holdings Limited: net property, plant and equipment
- Connect Biopharma Holdings Limited: share-based compensation expense
- Connect Biopharma Holdings Limited: operating income or loss
- Connect Biopharma Holdings Limited: current assets
- Connect Biopharma Holdings Limited: current liabilities
- Connect Biopharma Holdings Limited: current accounts payable
- Connect Biopharma Holdings Limited: net finite-lived intangible assets
- Connect Biopharma Holdings Limited: net current accounts receivable
- Connect Biopharma Holdings Limited: operating expenses
- Connect Biopharma Holdings Limited: research and development expense
Inspect the source
- Entity
- Connect Biopharma Holdings Limited / CIK 0001835268
- Captured
- 2026-09-21T17:30:39.828Z
- SEC response SHA-256
951eb5ddfa34f70de0a625897a19318774e2f42adac57b3ec995e85899f9a351
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001835268.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))